Sage Journals: Discover world-class research

Abstract

Background

Microbiological culture of cerebrospinal fluid is the gold standard to differentiate between aseptic and bacterial meningitis, but this method has low sensitivity. A fast and reliable new marker would be of interest in clinical practice.

Objective

Interleukin-6, secreted by T cells in response to meningeal pathogens and quickly delivered into cerebrospinal fluid, was evaluated as a marker of acute meningitis.

Design and Methods

A total of 150 cerebrospinal fluid samples were analysed by an electrochemiluminescence method, selected according to patient diagnosis: (a) bacterial meningitis confirmed by positive culture (n = 26); (b) bacterial meningitis with negative culture or not performed (n = 15); (c) viral meningitis confirmed by polymerase chain reaction or immunoglobulin G determination (n = 23); (d) viral meningitis with polymerase chain reaction negative or not performed (n = 42); and (e) controls (n = 44).

Results

Cerebrospinal fluid interleukin-6 concentration showed significant differences between all pathologic groups and the control group (P < 0.001). As a diagnostic tool for bacterial meningitis, interleukin-6 showed an area under the curve of 0.937 (95% confidence intervals: 0.895–0.978), significantly higher than those of classical biomarkers. An interleukin-6 cutoff of 1418 pg/mL showed 95.5% sensitivity and 77.5% specificity, whereas a value of 15,060 pg/mL showed 63.6% sensitivity and 96.7% specificity, for diagnosis of bacterial meningitis.

Conclusion

Interleukin-6 measured by electrochemiluminescence method is a promising marker for early differentiation between aseptic and bacterial meningitis. More studies are needed to validate clinical implications for future practice in an emergency laboratory.

Keywords

Meningitis interleukin-6 cerebrospinal fluid sensitivity specificity

Introduction

Meningitis is the inflammatory response of leptomeningeal cells and the subarachnoid space to injury that can be of infectious, chemical, tumoral or autoimmune aetiology. Acute infectious meningitis represents an important cause of emergency consultation, especially in paediatrics. Viral meningitis has a higher incidence than bacterial meningitis, but its clinical course is usually more benign.¹

In Spain, 3000–4000 new cases of meningitis are declared each year, with a mortality rate of up to 20%. It is estimated that approximately 70% of bacterial meningitis occur in children under five years of age, mainly due to three pathogens: Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. Most cases of viral meningitis are produced by enterovirus, the causal agent in up to 80–90% of cases.¹ Due to the high morbidity and mortality of meningitis, rapid diagnosis aimed at providing prompt and appropriate treatment is a priority.² The major diagnostic challenge is differentiating viral from bacterial pathogens, since the treatments are quite different. Clinical guidelines recommend initiating empirical antibiotic therapy in cases of suspected bacterial meningitis, despite the risk of microbial antibiotic resistance.

During the initial phase of either bacterial or viral meningitis, the clinical signs and symptoms are usually non-specific (headache, nuchal rigidity, fever, nausea and convulsions). Whenever meningitis is suspected, cerebrospinal fluid (CSF) is extracted by lumbar puncture to enable an aetiologic diagnosis by means of cell count, as well as biochemical and microbiological studies.

The gold standard for the diagnosis of septic meningitis is microbiological culture. However, this method shows low sensitivity³ and the diagnosis may be delayed. In untreated patients, Gram staining of CSF reveals the presence of bacteria in 50–80% of cases, and microbiological culture is positive in 85% of cases of bacterial meningitis.⁴ However, this percentage can decrease by up to 50% when the patient has been previously treated with antibiotics. Moreover, in microbiological culture, bacterial growth requires at least two days; for viral meningitis, culture may take even longer, although the most common pathogens (enterovirus and herpes simplex virus) can be detected with high sensitivity, by the polymerase chain reaction (PCR), reducing the laboratory turnaround time. Therefore, although microbiologic results are needed to confirm the bacterial infection and optimize the treatment, the initial aetiologic diagnosis of meningitis usually relies on the cytological and biochemical characteristics of CSF.

A cell count higher than 5 or 7 leukocytes/μL is considered pathological in adults and children, respectively, with a differential count being indicated after sample staining. Bacterial meningitis usually develops with pleocytosis (more than 1000 leukocytes/μL) and a clear predominance of polymorphonuclear cells (PMN) over lymphocytes. Conversely, viral meningitis produces a moderate pleocytosis, rarely over 1000 leukocytes/μL, showing clear lymphocyte predominance after the initial stages.^5,6 Thus, a leukocyte count does not allow early diagnosis of viral meningitis. Biochemical tests such as glucose and total protein provide complementary information. Viruses are the most common cause of aseptic meningitis (i.e. negative bacterial culture), although it is not always possible to demonstrate the viral origin of meningitis.⁵ Therefore, a faster and highly sensitive new method would be of interest in clinical practice.

Interleukin-6 (IL-6) is secreted by T cells, macrophages and fibroblasts. These cells mediate the immune response, and are involved in the regulation of the acute-phase response to injury and infection.⁷ Serum and umbilical cord blood IL-6 measurements have been described as a useful tool in the diagnosis of neonatal sepsis.⁸

In this study, we hypothesized that IL-6 may be delivered into CSF during septic meningitis. Subsequently, IL-6 may be detected after lumbar puncture and be useful as a biomarker for diagnosis and monitoring of these patients.

Materials and methods

During two periods (January 2008–June 2009 and February 2013–November 2013), 1326 CSF samples were received at the Department of Clinical Biochemistry, Hospital Universitario Central de Asturias (HUCA), Spain. A cohort of 377 patients who were admitted to the emergency department (ED) or intensive care unit (ICU) was retrospectively selected. Patients with a clinical diagnosis of meningitis (fever, headache and meningeal signs) and sufficient sample volume after performing routine tests were included as cases (n = 106). In order to minimize the potential bias of retrospective selection, the control cohort was randomly selected among those 271 patients with CSF sample collection and non-infectious diagnosis (e.g. headache, hydrocephaly, Alzheimer’s disease, dementia, facial paralysis and amnesia). Approximately one control was therefore included per two cases (n = 44). Exclusion criteria for both groups were: incomplete medical records, CSF collected ≥ 4 days after symptoms onset, diagnosis of cancer and other infectious diseases (e.g. acute otitis media, pneumonia). Informed consent was obtained from all patients, according to our institution protocol.

The CSF cell count was carried out immediately after specimen collection into sterile tubes following European Federation of Neurological Societies (EFNS) clinical guidelines.⁹ One CSF sample was analysed per patient, as a part of their diagnostic process, and a differential leukocyte count was performed on the stained sample, when more than 6 or 20 leukocytes/μL were observed, in adults and children, respectively. After differential count, when needed, all the CSF samples were centrifuged at 1500 g for 5 min in order to measure glucose and total protein. Aliquots of supernatants were frozen at −80℃ until being analysed for IL-6 measurement.¹⁰

Another CSF sample was routinely sent to microbiology laboratory for specific tests according to individual clinical suspicion. Bacterial tests panel included Gram staining, culture and antibiogram. Viral PCR tests were applied for enterovirus, herpes virus-1, herpes virus-2, Epstein-Barr virus, cytomegalovirus and parvovirus. Immunoglobulin G (IgG) test was used for varicella zoster virus.

Consideration of bacterial meningitis depended on clinical criteria and presence of more than 60% PMN in differential white cell count, with total >100 leukocytes/µL, as well as decreased CSF/blood glucose ratio (<0.4). Similarly, viral meningitis was suspected whenever there was a predominance of lymphocytes and a normal CSF/blood glucose ratio.

Samples were classified into five groups, according to the final diagnosis, before being processed for this study: (a) bacterial meningitis confirmed by positive culture (n = 26); (b) bacterial meningitis with negative culture or not performed (n = 15); (c) viral meningitis confirmed by PCR or IgG determination (n = 23); (d) viral meningitis with PCR negative or not performed (n = 42); (e) controls (n = 44).

IL-6 was measured in a Cobas e-601 analyzer (Roche Diagnostics) at the state laboratory of the HUCA (Oviedo, Spain), by an electrochemiluminescence (ECLIA) method able to provide a result within 19 min. This method has been standardized against the National Institute for Biological Standards and Control’s (NIBSC) first international standard (89/548). The limit of detection was 1.5 pg/mL, and linearity up to 5000 pg/mL was observed. When higher IL-6 concentrations were obtained, (>5000 pg/mL) samples were diluted 1:10. However, some samples (n = 14) showed concentrations higher than 50,000 pg/mL after the first dilution, without enough volume for further redilution; the value of 50,000 pg/mL was assigned for these samples during statistical analysis.

The imprecision of the method had already been estimated by using a pool of plasma samples for low concentrations (experimental mean 3.20 pg/mL), showing 7.6% and 8.0% of intra- and inter-assay variability.¹¹ Quality control material for medium and high concentrations (PreciControl MultiMaker, 33.3 pg/mL and 210 pg/mL, respectively) showed coefficient of variation (CV) of 3.0% and 1.0%, respectively, for intra-assay, with the inter-assay CV being 4.5% and 3.7%, respectively.

No significant cross-reactions were described with other interleukins: IL-1, IL-2, IL-3, IL-4, IL-8, γ-interferon and TNF-α.

Statistical analysis was performed with SPSS Statistics software (IBM version 19) and MedCalc (version 12.5). A P value < 0.05 was considered statistically significant. Medians, minimum, maximum and interquartile ranges were calculated for descriptive purposes. Normal distribution of marker concentrations was tested using the Kolmogorov–Smirnov test. Mann-Whitney U test and Kruskal–Wallis test were carried out to compare different groups for non-normally distributed variables. Receiver operating characteristic (ROC) curves analysis was carried out to study the marker’s diagnostic power. The area under the ROC curve was statistically compared by the Hanley and McNeil test.

Results

Mean age, sex distribution and other population characteristics from all patients are summarized in Table 1.

Table 1.

Population characteristics and classic markers from all patients included in the study.

Variable	Group A	Group B	Group C	Group D	Group E
Patients^a	26 (11.5%)	15 (6.6%)	23 (34.7%)	42 (30.9%)	44 (4.5%)
Age (years)^b	46.0 (0–88)	62.0 (13–90)	38.5 (0–83)	35.5 (0–78)	50.0 (0–82)
Women, n (%)	10 (38.5)	11 (73.3)	7 (30.4)	20 (47.6)	22 (50)
CSF time collection (days)^c	2.00 (0.00–2.00)	2.00 (1.75–3.00)	1.50 (1.00–3.00)	1.00 (1.00–3.25)	n/a
Red cells (count/μL)^c	145 (14–1000)	548 (12–2043)	16 (2–239)	27 (3–291)	17 (4–29)
Leukocyte (count/μL)^c	1603 (229–3570)	408 (47–2836)	150 (74–239)	134 (43–314)	22 (19–25)
% Polymorphonuclear cells^c	88.0 (83.0–97.3)	68.5 (37.3–91.8)	11.5 (3.8–84.2)	29.5 (11.3–58.0)	n/a
Glucose (mmol/L)^c	2.03 (1.11–3.57)	1.78 (0.41–3.16)	3.52 (2.97–4.16)	3.39 (3.00–3.96)	3.66 (3.50–3.83)
CSF:blood glucose ratio^c	0.31 (0.15–0.48)	0.26 (0.09–0.45)	0.57 (0.49–0.61)	0.57 (0.51–0.62)	0.43 (0.27–0.59)
Total protein (mg/dL)^c	195 (92.6–302)	163 (71.2–459)	73.2 (36.0–87.0)	56.4 (32.6–74.9)	32.4 (25.8–39.0)
Community-acquired meningitis, n (%)	16 (61.5)	7 (46.6)	22 (95.5)	41 (97.6)	n/a

CSF: cerebrospinal fluid.

Results are expressed as total patients (% paediatric patients, age ≤ 13 years). ^bMedian (total age range). ^cMedian (interquartile interval).

Diverse pathogens were found in the 49 CSF samples from groups A and C (46.2% of cases). Among those from group A, the most common were Staphylococcus aureus (n = 5), Staphylococcus epidermidis (n = 5), S. pneumoniae (n = 4), Escherichia coli (n = 3), Listeria monocytogenes (n = 3), N. meningiditis (n = 3) and H. influenzae (n = 2). No relationship could be established between CSF IL-6 concentrations and the pathogen. For group C, the pathogens most commonly found were enterovirus (n = 10), herpes simplex virus-1 (n = 5) and varicella zoster virus (n = 4).

Patient outcomes for each group are shown in Table 2. Of 106 cases, four patients (3.77%) died from meningitis and other four (3.77%) from other concomitant diseases (e.g. ischemic stroke, liver failure).

Table 2.

Outcomes of all the followed case-patients stratified according to pathologic groups.

	Group
Outcome	A	B	C	D	Total
No complications	8	6	12	33	59
Neurological after-effects	7	2	7	6	22
Death from meningitis	3	0	1	0	4
Death from other causes	2	1	1	0	4
Unknown	6	6	2	3	17
Total	26	15	23	42	106

Six patients (40%) in group B (bacterial meningitis not confirmed) had antibiotic therapy administered 72 h prior to admission, but in group A (bacterial meningitis confirmed) this percentage decreased by up to 23.1%. In group B (n = 15), five out of the six patients treated with antibiotics showed negative cultures but, in the other one, CSF culture had not been performed. The nine remaining patients of this group were not treated with antibiotics, six showing negative culture whereas the other three were not performed.

The IL-6 concentration was determined for all the groups, as well as the median and 95% confidence intervals (CI) calculated for each group. CSF IL-6 concentration showed significant differences between the control group and all other groups (P < 0.001) (Figure 1), as well as between bacterial meningitis confirmed by culture (group A, IL-6 median: 39,157 pg/mL) and the other groups (P = 0.006 for group B [IL-6 median: 5983 pg/mL] and P < 0.001 for groups C, D and E [IL-6 median: 601, 887 and 3.67 pg/mL, respectively]). On the other hand, the interesting comparison between IL-6 and percentage PMN performances was not considered as an option, since 25% of CSF samples from groups C and D (n = 13) and 40 of the 44 samples from group E (91%) did not meet the criteria to perform a differential count, thus lowering the statistical power of the study.

Figure 1.

Distribution of IL-6 concentrations and % PMN on CSF from different study groups: (a) bacterial meningitis confirmed by positive culture, (b) clinical suspicion of bacterial meningitis with negative or not performed culture, (c) viral meningitis confirmed by polymerase chain reaction (PCR) or IgG determination, (d) clinical suspicion of viral meningitis with negative or not performed PCR and (e) control group.

We found three IL-6 outlier values in group B (Table 3). These CSF samples could be suggestive of bacterial meningitis, but since culture was not performed or negative, there was no microbiological confirmation. This is the reason why they have been classified into group B instead of group A.

Table 3.

Outlier values in group B (bacterial meningitis not confirmed by microbiological tests).

Outlier	IL-6 (pg/mL)	Leukocytes/ μL	PMN cells (%)	Glucose (mmol/L)	CSF/blood glucose ratio	Total proteins (mg/dL)	Prior antibiotherapy	Culture
1	50,000	1258	85	0.50	N/A	265	No	Not performed
2	50,000	7830	93	0.44	0.10	486	No	Negative
3	50,000	7907	94	0.28	0.04	505	Yes	Negative

IL-6: interleukin-6; PMN: polymorphonuclear cells; CSF: cerebrospinal fluid.

There was also another outlier value in group D (IL-6: 49,000 pg/mL). Routine tests results were as follows: 304 leukocytes/μL (54% PMN cells), CSF glucose: 4.22 mmol/L, CSF/blood glucose ratio: 0.38; total proteins: 173 mg/dL. No recent prior antibiotic therapy, negative culture and viral studies were performed. This sample could not be classified into group A or C because there was no confirmation by microbiological techniques. Moreover, classical biochemical parameters were discordant: low CSF/blood glucose ratio with low percentage of PMN cells.

When CSF IL-6 was tested as a diagnostic tool for bacterial meningitis (group A), an area under the curve (AUC) of 0.937 (95% CI: 0.895–0.978) was obtained. Figure 2 shows the comparison between the AUC of CSF IL-6 and classical markers, such as CSF leukocyte count (AUC 0.872; 95% CI: 0.802–0.943), total protein concentration (AUC 0.795; 95% CI: 0.680–0.910) and decrease of CSF/blood glucose ratio (AUC 0.865; 95% CI: 0.791–0.939). Statistically significant differences were found for all three comparisons, demonstrating the higher diagnostic power of IL-6 despite having found some degree of overlap between the respective ROC curves. Selecting a CSF IL-6 cut-off value of 1418 pg/mL, 95.5% sensitivity and 77.5% specificity were obtained for the diagnosis of bacterial meningitis, whereas concentrations higher than 15,060 pg/mL showed 63.6% sensitivity and 96.7% specificity. On the other hand, the best classical biomarker was the CSF/blood glucose ratio, showing 95.5% sensitivity and 60.8% specificity at a cut-off value of 0.545 (Table 4). It is important to point out, however, that in six patients from group A the ratio could not be calculated: two of them because no blood sample had been obtained at admission and the other four because the value of CSF glucose was below the detection limit of our method (<0.11 mmol/L, enzymatic hexokinase reference method); therefore, these patients had to be excluded from the numerical analysis. However, the usual cut-off value of 0.4 for CSF/blood glucose ratio only showed 59.1% sensitivity and 89.2% specificity. Additionally, a conventional cutoff of 100 cells/μL for the leukocyte count only achieved 81.8% sensitivity and 68.3% specificity.

Figure 2.

Comparison of the diagnostic power of IL-6 and classic biomarkers for bacterial meningitis confirmed by positive culture (group A).

Table 4.

Cut-off points showing the best sensitivity or specificity for each marker on diagnosis of bacterial meningitis.

Biomarker	Cutoff	Sensitivity (%)	Specificity (%)
IL-6 (pg/mL)	1418	95.5	77.5
IL-6 (pg/mL)	15,060	63.6	96.7
Cell count (leukocytes/mL)	48	95.5	60.8
	100	81.8	68.3
	1127	45.5	96.7
Glucose (mmol/L)	4.27	95.5	14.2
Glucose (mmol/L)	0.67	9.1	96.7
CSF:blood glucose ratio	0.545	95.5	64.2
	0.400	59.1	89.2
	0.165	27.3	96.7
Total proteins (mg/dL)	27.85	95.5	12.5
Total proteins (mg/dL)	272.3	27.3	96.7

IL-6: interleukin-6; CSF: cerebrospinal fluid.

Discussion

The diagnosis of meningitis is based on the clinical presentation of the patient and the cytological and biochemical characteristics of CSF obtained by lumbar puncture.^1,12 Establishing the aetiology of meningitis is essential, if appropriate treatment is to be administered promptly. Unlike viral or aseptic meningitis, bacterial meningitis may be fatal, especially if diagnosis and antimicrobial therapy are delayed.^13,14

Low CSF glucose concentrations (<2.22 mmol/L) are present in approximately 50–60% of cases of bacterial meningitis; often CSF protein is increased. However, the CSF/blood glucose ratio provides better diagnostic performance (a ratio ≤ 0.4 theoretically showing up to 80% sensitivity and 98% specificity). On the other hand, Gram staining of CSF allows rapid diagnosis in 60–90% of cases of bacterial meningitis, but the false negative rate is high. Microbiological culture of CSF is positive in 70–85% of cases of bacterial meningitis¹ but at least 48 h are required to obtain a result. Thus, microbiological tests are more useful to confirm the infection and optimize the antibiotic treatment than for diagnosis.

For all these reasons, finding new biochemical markers that allow fast and reliable diagnosis of meningitis is of great value. The potential usefulness of measuring inflammatory biomarkers, such as C-reactive protein (CRP), in bacterial meningitis has been previously evaluated.^15,16,17 However, controversial results were described with sensitivities ranging from 18 to 100% and specificities between 75 and 100% according to different cut-off points. Procalcitonin (PCT) has also been postulated as an efficient marker for the differential diagnosis of meningitis,^18,19,20 but Viallon et al.²¹ found undetectable concentrations of PCT in most of the 105 CSF samples analysed from different patients, including both viral and bacterial meningitis; on the other hand, Shimetani et al.²² showed that PCT concentrations in patients with bacterial meningitis were higher in serum than in CSF samples.

IL-6 has been regarded as a useful marker for the diagnosis of neonatal sepsis in either umbilical cord blood or neonatal serum,^23,24 especially during the first 48 h of life due to better kinetic profile than PCT in those patients. Interestingly, several studies have demonstrated that high CSF IL-6 levels can be found in bacterial and viral meningitis.^25,26,27 However, slight elevations of CSF IL-6 levels have also been found in patients with schizophrenia, major depressive disorder, trauma and after exhaustive exercise.^25,28,29

Fast, highly sensitive tests that can help in the differential diagnosis of bacterial from aseptic meningitis would be of great interest. In the present study, IL-6 was able to discriminate between both aetiologies at an IL-6 cutoff of 1418 pg/mL showing 95.5% sensitivity and 77.5% specificity for bacterial meningitis. Classical tests reached the same sensitivity only at a cost of lower specificities: 60.8% and 64.2% for a cut-off point of 48 leukocytes/mL and 0.545 CSF/blood glucose ratio, respectively, that differ considerably from the classical cutpoints well established in clinical practice (Table 4). In fact, IL-6 showed significantly higher diagnostic power (Figure 2) when compared to classic biomarkers (P < 0.05).

However, our proposed IL-6 cutoffs disagree with those previously published. Taskin et al. (Accucyte ELISA) showed that IL-6 in CSF could be an early marker in differential diagnosis of bacterial and viral meningitis as well as other diseases causing meningeal irritation, showing a mean IL-6 of 349.3 (± 169.2) pg/mL for the diagnosis of bacterial meningitis.⁴ Prasad et al. (RayBio ELISA)²⁷ proposed an IL-6 cut-off level of 300 pg/mL for bacterial meningitis with 87.5% sensitivity and 53% specificity. Other authors described even much lower CSF IL-6 concentrations than ours in bacterial meningitis. For instance, Mukai et al. (Quantikine HS ELISA)³⁰ and Hsieh et al. (R&D Systems ELISA)³¹ reported a median of 70.37 pg/mL and 45.2 pg/mL, respectively, whereas Vázquez et al. (Immulite ELISA)²⁶ showed 92.3% sensitivity and 100% specificity with a cutoff of 90 pg/dL. On the other hand, Pinto-Junior et al. (R&D Systems ELISA)³² found a mean of 536 pg/mL for bacterial meningitis, but a mean of 415 pg/mL for aseptic meningitis, with no significant differences. Nevertheless, all these studies have several limitations. First, the numbers of cases of bacterial meningitis (n = 6 to 13) were smaller than in our study, and the selected population was truncated by age. Second, there are different criteria for classifying a patient in either group, and not all cases of bacterial or viral meningitis were confirmed by microbiological tests. Third and last, many of these studies were performed with ELISA kits, some of which had not been validated for in vitro diagnostic purposes, while our study was performed using the most recent electrochemiluminescence (ECLIA) method. Immunoassays have a significant variability of results depending on the method used (ECLIA, ELISA or radioimmunoassay), not only because of analytical differences (ECLIA being the most sensitive and reproducible) but also since monoclonal antibodies provided by different manufacturers may recognize different IL-6 epitopes or isoforms.³³ Our group described the lack of transferability between a semi-quantitative immunoassay and the ECLIA method for IL-6 determinations showing the need for reappraisal of cut-off thresholds based on clinical findings for neonatal patients at risk for sepsis.¹¹

In our study, outlier values (IL-6 ≥ 50.000 pg/mL) were not only found in group A (n = 11), but also in B, where culture had been negative (n = 2) or not performed (n = 1) and group D (n = 1, IL6 = 49,000 pg/mL). Cytokines are too large and hydrophobic to cross the blood–brain barrier by membrane diffusion. Blood–brain transport has been described for some cytokines (including IL-6) but is saturable.^34,35 This, as well as review of the medical records of these patients, allowed us to discard systemic inflammation as a potential cause of the observed CSF IL-6 increased concentrations. In fact, our patients were treated with antibiotics, despite not being definitely diagnosed by classic biomarkers. On the other hand, clinical guidelines indicate that empiric treatment with antibiotic should be started as soon as possible if there is suspected meningitis. This is justified due to the seriousness of bacterial meningitis and its associated outcome.^1,36 Also, concomitant symptoms (headache, fever) cause some patients to take antibiotics on their own. This has an influence on the culture preventing bacteria growth and making medical diagnosis difficult, so some bacterial meningitis presenting few symptoms are incorrectly labelled as viral meningitis. In our study, six patients (40%) in group B (bacterial meningitis not confirmed) had antibiotic therapy administered within 72 h prior to admission but in group A (bacterial meningitis confirmed) this percentage decreased by up to 23.1%.

Finally, the retrospective design of the present study allows for the possibility of bias. Randomized selection of controls aimed to minimise this effect. However, our results provide a basis for further prospective studies to establish the diagnostic role of CSF-IL-6 in clinical practice.

Conclusion

In the present study, measurement of CSF IL-6 by automated ECLIA has been demonstrated to be a potentially useful tool to aid the management of patients under suspicion of meningitis. Prospective studies are needed to validate these findings.

Footnotes

Acknowledgements

The authors thank Roche diagnostics for providing reagent kits.

Conflict of interest

None.

Funding

IL-6 reagent was supplied by Roche Diagnostics.

Ethical approval

The ethical committee of clinical research of the Principality of Asturias, Ref 002/14.

Guarantor

FVA.

Contributorship

PG, BP and FVA researched the literature and conceived the study. PG and VR analysed the samples. PG and BP performed the statistical analysis. PG wrote the first draft of the manuscript. BP and EM reviewed and modified the paper. All authors reviewed and approved the final version of the manuscript.

References

Tunkel

Hartman

Kaplan

. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267–1284.

Baraff

Lee

Schriger

. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12: 389–394.

Cordeiro

Harcourt

. Accuracy of real-time PCR, Grain stain and culture for Streptococcus pneuomiae, Neisseria meningitides and Haemophilus influenza meningitis diagnosis. BMC Infect Dis 2013; 22: 13–26.

Taskin

Turgut

Kilic

. Serum procalcitonin and cerebrospinal fluid cytokines level in children with meningitis. Mediators Inflamm 2004; 13: 269–273.

Negrini

Kelleher

Wald

. Cerebrospinal fluid findings in aseptic versus bacterial meningitis. Pediatrics 2000; 105: 316–319.

NCCLS. Body fluids analysis for cellular composition: proposed guideline [NCCLS document H56-P, ISBN 1-56238-575-5]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania: NCCLS, USA, 2003.

Heinrich

Behrmann

Haan

. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J 2003; 15: 374: 1–20.

Goepfert

Andrews

Carlo

. Umbilical cord plasma interleukin-6 concentrations in preterm infants and risk of neonatal morbidity. Am J Obstet Gynecol 2004; 191: 1375–1381.

Deisenhammer

Bartos

Egg

. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 2006; 13: 913–922.

10.

Kenis

Teunissen

De jongh

. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine 2002; 19: 228–235.

11.

Prieto

Miguel

Costa

. New quantitative electrochemiluminiscence method (ECLIA) for interleukin-6 (IL-6) measurement. Clin Chem Lab Med 2010; 48: 835–838.

12.

Bonadio

. The cerebrospinal fluid: physiologic aspects and alterations associated with bacterial meningitis. Pediatr Infect Dis J 1992; 11: 423–431.

13.

Tunkel

Scheld

. Issues in the management of bacterial meningitis. Am Fam Physician 1997; 56: 1355–1362.

14.

Heckenberg

Brouwer

van de Beek

. Bacterial meningitis. Handb Clin Neurol 2014; 121: 1361–1375.

15.

Macfarlane

Narla

. Cerebrospinal fluid C-reactive protein in the laboratory diagnosis of bacterial meningitis. Acta Paediatr Scand 1985; 74: 560–563.

16.

Abramson

Hampton

Babu

. The use of C-reactive protein from cerebrospinal fluid for differentiating meningitis from other central nervous system diseases. J Infect Dis 1985; 151: 854–858.

17.

Nathan

Scheld

. The potential roles of C-reactive protein and procalcitonin concentrations in the serum and cerebrospinal fluid in the diagnosis of bacterial meningitis. Curr Clin Top Infect Dis 2002; 22: 155–165.

18.

Gendrel

Raymond

Assicot

. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997; 24: 1240–1242.

19.

Gendrel

Raymond

Assicot

. Procalcitonin, C-reactive protein and interleukin 6 in bacterial and viral meningitis in children. Presse Med 1998; 27: 1135–1139.

20.

Jereb

Muzlovic

Hojker

. Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Infection 2001; 29: 209–212.

21.

Viallon

Zeni

Lambert

. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis 1999; 28: 1313–1316.

22.

Shimetani

Mori

. Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. Scand J Clin Lab Invest 2001; 61: 567–574.

23.

Chang

Han

. Inflammatory markers in cord blood or maternal serum for early detection of neonatal sepsis-a systemic review and meta-analysis. J Perinatol 2014; 34: 268–274.

24.

Shahkar

Keshtkar

Mirfazeli

. The role of IL-6 for predicting neonatal sepsis: a systematic review and meta-analysis. Iran J Pediatr 2011; 21: 411–417.

25.

Gruol

Nelson

. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997; 15: 307–339.

26.

Vázquez

Adducci

Coll

. Acute meningitis prognosis using cerebrospinal fluid interleukin-6 levels. J Emerg Med 2012; 43: 322–327.

27.

Prasad

Kapoor

Srivastava

. Cerebrospinal Fluid TNF-α, IL-6, and IL-8 in children with bacterial meningitis. Pediatr Neurol 2014; 50: 60–65.

28.

Kiliç

Ulusoy

Cirrik

. Effect of exercise intensity on cerebrospinal fluid interleukin-6 concentration during recovery from exhaustive exercise in rats. Acta Physiol Hung 2013; 5: 1–11.

29.

Sasayama

Hattori

Wakabayashi

. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 2013; 47: 401–406.

30.

Mukai

Krebs

VLJ

Bertoli

. TNF-α and IL-6 in the diagnosis of bacterial and aseptic meningitis in children. Pediatr Neurol 2006; 34: 25–29.

31.

Hsieh

Chen

. Cerebrospinal fluid levels of interleukin-6 and interleukin-12 in children with meningitis. Child’s Nerv Syst 2009; 25: 461–465.

32.

Pinto-Junior

Rebelo

Gomes

. IL-6 and IL-8 in cerebrospinal fluid from patients with aseptic meningitis and bacterial meningitis: their potential role as a marker for differential diagnosis. Braz J Infect Dis 2011; 15: 156–158.

33.

Brailly

Montero-Julian

Zuber

. J. Total interleukin-6 in plasma measured by immunoassay. Clin Chem 1994; 40: 116–123.

34.

Banks

Kastin

Gutiérrez

. Penetration of interleukin-6 across the blood-brain barrier. Neurosci Lett 1995; 179: 53–56.

35.

Banks

Lynch

Price

Cytokines and the blood-brain barrier. In: Siegel

Zalcman

(eds). The neuroimmunological basis of behavior and mental disorders, New York: Springer, 2009, pp. 3–17.

36.

Prasad

Karlupia

. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med 2007; 101: 2037–2043.

Interleukin-6 in cerebrospinal fluid as a biomarker of acute meningitis

Abstract

Background

Objective

Design and Methods

Results

Conclusion

Keywords

Introduction

Materials and methods

Results

Discussion

Conclusion

Footnotes

Acknowledgements

Conflict of interest

Funding

Ethical approval

Guarantor

Contributorship

References